Growth in children receiving contemporary disease specific therapy for Crohn's disease

S. Malik, A. Mason, Andisheh Bakhshi, David Young, J. Bishop, V. Garrick, P. McGrogan, R.K. Russell, S.F Ahmed

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

It is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD). To assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD. Growth retardation may occur in children with Crohn's disease (CD). Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids. Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease. The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9-15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4-19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF. At T0, mean height SD score (HtSDS) was -0.5 (-3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (-2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was -0.6 (-4.8 to 7.8), -0.6 (-2.9 to 2.2), -0.7 (-3.6 to 2.5) and -0.5 (-3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was -1.4 (-7.4 to 7.4), -0.6 (-7.5 to 6.1), -0.1 (-6.6 to 7.6) and 0.6 (-4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02). Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases
LanguageEnglish
Pages698-703
Number of pages6
JournalArchives of Disease in Childhood
Volume97
Issue number8
Early online date9 Jun 2012
DOIs
Publication statusPublished - 2012

Fingerprint

Crohn Disease
Growth
Therapeutics
Prednisolone
Chronic Disease
Weights and Measures
Azathioprine
Methotrexate
Glucocorticoids

Keywords

  • Crohn's disease
  • children
  • child health
  • prednisolone
  • medical statistics

Cite this

Malik, S. ; Mason, A. ; Bakhshi, Andisheh ; Young, David ; Bishop, J. ; Garrick, V. ; McGrogan, P. ; Russell, R.K. ; Ahmed, S.F . / Growth in children receiving contemporary disease specific therapy for Crohn's disease. In: Archives of Disease in Childhood. 2012 ; Vol. 97, No. 8. pp. 698-703.
@article{da1adda29a734cd59bc76ddf49405fe0,
title = "Growth in children receiving contemporary disease specific therapy for Crohn's disease",
abstract = "It is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD). To assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD. Growth retardation may occur in children with Crohn's disease (CD). Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids. Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease. The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9-15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4-19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF. At T0, mean height SD score (HtSDS) was -0.5 (-3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (-2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was -0.6 (-4.8 to 7.8), -0.6 (-2.9 to 2.2), -0.7 (-3.6 to 2.5) and -0.5 (-3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was -1.4 (-7.4 to 7.4), -0.6 (-7.5 to 6.1), -0.1 (-6.6 to 7.6) and 0.6 (-4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02). Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases",
keywords = "Crohn's disease , children, child health, prednisolone , medical statistics",
author = "S. Malik and A. Mason and Andisheh Bakhshi and David Young and J. Bishop and V. Garrick and P. McGrogan and R.K. Russell and S.F Ahmed",
year = "2012",
doi = "10.1136/archdischild-2011-300771",
language = "English",
volume = "97",
pages = "698--703",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "8",

}

Malik, S, Mason, A, Bakhshi, A, Young, D, Bishop, J, Garrick, V, McGrogan, P, Russell, RK & Ahmed, SF 2012, 'Growth in children receiving contemporary disease specific therapy for Crohn's disease' Archives of Disease in Childhood, vol. 97, no. 8, pp. 698-703. https://doi.org/10.1136/archdischild-2011-300771

Growth in children receiving contemporary disease specific therapy for Crohn's disease. / Malik, S.; Mason, A.; Bakhshi, Andisheh; Young, David; Bishop, J.; Garrick, V.; McGrogan, P.; Russell, R.K.; Ahmed, S.F .

In: Archives of Disease in Childhood, Vol. 97, No. 8, 2012, p. 698-703.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Growth in children receiving contemporary disease specific therapy for Crohn's disease

AU - Malik, S.

AU - Mason, A.

AU - Bakhshi, Andisheh

AU - Young, David

AU - Bishop, J.

AU - Garrick, V.

AU - McGrogan, P.

AU - Russell, R.K.

AU - Ahmed, S.F

PY - 2012

Y1 - 2012

N2 - It is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD). To assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD. Growth retardation may occur in children with Crohn's disease (CD). Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids. Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease. The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9-15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4-19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF. At T0, mean height SD score (HtSDS) was -0.5 (-3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (-2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was -0.6 (-4.8 to 7.8), -0.6 (-2.9 to 2.2), -0.7 (-3.6 to 2.5) and -0.5 (-3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was -1.4 (-7.4 to 7.4), -0.6 (-7.5 to 6.1), -0.1 (-6.6 to 7.6) and 0.6 (-4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02). Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases

AB - It is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD). To assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD. Growth retardation may occur in children with Crohn's disease (CD). Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids. Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease. The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9-15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4-19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF. At T0, mean height SD score (HtSDS) was -0.5 (-3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (-2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was -0.6 (-4.8 to 7.8), -0.6 (-2.9 to 2.2), -0.7 (-3.6 to 2.5) and -0.5 (-3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was -1.4 (-7.4 to 7.4), -0.6 (-7.5 to 6.1), -0.1 (-6.6 to 7.6) and 0.6 (-4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02). Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases

KW - Crohn's disease

KW - children

KW - child health

KW - prednisolone

KW - medical statistics

UR - http://www.scopus.com/inward/record.url?scp=84864710535&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2011-300771

DO - 10.1136/archdischild-2011-300771

M3 - Article

VL - 97

SP - 698

EP - 703

JO - Archives of Disease in Childhood

T2 - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 8

ER -